Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HOT-1030
- Development stage
- Phase 1
- Lead developer
- Shanghai Huaota Biopharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
HOT-1030 is a recombinant humanized IgG1 monoclonal antibody that acts as an agonist of CD137 (also known as 4-1BB or TNFRSF9), a member of the tumor necrosis factor receptor superfamily. It specifically binds to the CRD1 region in the extracellular domain of human 4-1BB with high affinity, without blocking its natural ligand (4-1BBL). By activating 4-1BB signaling on immune cells such as activated T cells, NK cells, and dendritic cells, HOT-1030 promotes proliferation and survival of CD8+ T cells and enhances anti-tumor immune responses. The drug is being developed for intravenous administration in patients with advanced malignant solid tumors[1][2][3][5].
- Other names
- HOT1030HOT-1030HOT 1030
02
Targets
TNFRSF9 (CD137 extracellular domain)
Beyond the preview
Go deeper on HOT-1030.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HOT-1030.